AMGEN INC — Director's Dealing 2018

Jun 26, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kezar Life Sciences, Inc. (KZR)
CIK: 0001645666
Period of Report: 2018-06-25

Reporting Person: Onyx Therapeutics, Inc. (10% Owner)
Reporting Person: AMGEN INC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-25	Common Stock	C	1121384	—	Acquired	1121384	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-25	Series A Redeemable Convertible Preferred Stock	$	C	1121384	Disposed		Common Stock (1121384)	Direct

Footnotes

F1: As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock.

F2: These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx.

F3: Upon the closing of the Issuer's initial public offering on the date hereof, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock.